Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Leon Berard
Stereotactic radiotherapy or SBRT (Body Stereotactic Radiation Therapy) allows to irradiate with high dose limited lesions size with a local control surrounding of 80-98% and with a low level of toxicity.
We propose to realize a classic concomitant RT-CT for mediastinal irradiation and combine this treatment with stereotactic RT for peripheral primary tumor.
The estimated inclusion period is approximately 3 years.
Follow-up duration for each patient is 2 years. The duration of the research is 5 years.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years ≤ Age ≤ 75 years
PS ECOG 0 or 1
Histologically proven NSCLC
Unresectable stage III: T1 or T2 or T3 ≤ 5 cm AND N2 or N3 (only contralateral mediastinum or homolateral supraclavicular).
Peripheral primary tumor ≥ 1 cm and ≤ 5 cm
Possible concomitant chemoradiotherapy : 1 cure induction and 3 concomitant cycles of chemotherapy with cisplatin and Navelbine ® and 3D conformal radiotherapy delivering 66 Gy in 33 fractions to the mediastinal lymph node involvement without treating the peripheral tumor.
Adequate biological parameters
Forced expiratory volume (FEV) ≥1 liter or ≥ 30% of the theoretical value
Patient covered by a health insurance scheme
Signed informed consent
You may not be if
SCLC or large cell neuroendocrine carcinoma
Metastatic disease
Stage IVa
Pregnant or breast-feeding women
Clareo Health | Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor
